1572-Targeting 5-HT2AR to Enhance Colorectal Cancer Immunity
This research article describes the discovery of a gut-immune axis that can be leveraged to treat colorectal cancer (CRC). Scientists found that lysergic acid diethylamide (LSD) slows tumor growth by activating 5-HT2AR receptors, though its use is limited by its hallucinogenic properties. To address this, the researchers developed IHCH-8110, a specialized non-brain-penetrant agonist that targets these receptors in the peripheral nervous system without affecting the brain. This compound activates enteric glial cells, which then release signaling proteins that recruit and empower CD8+ T cells…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.